Sanofi (NYSE:SNY) touted data today from its 10,000-patient Lightning study, which evaluated electronic medical records of adults with Type II diabetes to study its long-acting insulin glargine injection, Toujeo.
The company found that Toujeo significantly lowered patients’ risk of experiencing severe low blood sugar compared to other long-acting insulin, like its own Lantus product.
Get the full story at our sister site, Drug Delivery Business News.
The post Sanofi touts real-world data for Toujeo insulin glargine injection appeared first on MassDevice.